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Intravenous vitamin D is standard therapy for secondary
hyperparathyroidism in hemodialysis (HD) patients. In
for-profit dialysis clinics, mortality was higher for patients
on calcitriol compared to paricalcitol. Doxercalciferol, a
second vitamin D2 analog, is currently available. We assessed
mortality associated with each vitamin D analog and with
lack of vitamin D therapy in patients who began HD at
Dialysis Clinic Inc. (DCI), a not-for-profit dialysis provider.
During the 1999–2004 study period we studied 7731 patients
(calcitriol: n¼ 3212; paricalcitol: n¼ 2087; doxercalciferol:
n¼ 2432). Median follow-up was 37 weeks. Mortality rates
(deaths/100 patient-years) were identical in patients on
doxercalciferol (15.4, 95% confidence interval (13.6–17.1))
and paricalcitol (15.3 (13.6–16.9)) and higher in patients on
calcitriol (19.6 (18.2–21.1)) (Po0.0001). In all models mortality
was similar for paricalcitol versus doxercalciferol (hazard
ratios¼ 1.0). In unadjusted models, mortality was lower in
patients on doxercalciferol (0.80 (0.66, 0.96)) and paricalcitol
(0.79 (0.68, 0.92)) versus calcitriol (Po0.05). In adjusted
models, this difference was not statistically significant. In all
models mortality was higher for patients who did not receive
vitamin D versus those who did (1.2 (1.1–1.3)). Mortality in
doxercalciferol- and paricalcitol-treated patients was virtually
identical. Differences in survival between vitamin D2 and D3
may be smaller than previously reported.
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Despite recent therapeutic advances, mortality remains high
among patients with stage five chronic kidney disease
maintained on hemodialysis (HD).1 The excess mortality,
largely attributable to atherosclerotic cardiovascular disease
(ASCVD), remains significant even after controlling for age,
diabetes, and hypertension.1 These observations are consis-
tent with the hypothesis that non-traditional ASCVD risk
factors, including malnutrition, and inflammation, may
contribute to the observed excess mortality.2,3
Another non-traditional risk factor, disordered mineral
metabolism, has been postulated to play an important role in
the pathogenesis of ASCVD among HD patients.4–7 Abnorma-
lities in serum calcium, phosphorus, and parathyroid
hormone (PTH) have been associated with increased all-
cause and ASCVD morbidity, and mortality.8–14 The attribu-
table risk for mortality associated with disorders of mineral
metabolism (17.5%) has been described to be higher than that
for inefficient dialysis (5.1%) and anemia (11.3%).11 Accord-
ingly, the National Kidney Foundation (NKF) Kidney Disease
Outcomes Quality Improvement (KDOQI) work group has
issued guidelines for serum calcium, phosphorus, calcium–-
phosphorus product, and PTH.15
Intravenous vitamin D is mainstream therapy for the
treatment of secondary hyperparathyroidism among HD
patients.15,16 Calcitriol (1a,25-dihydroxyvitamin D3; Calcijex,
Abbott Laboratories, North Chicago, IL, USA), the first
available vitamin D analog,17 effectively lowers serum PTH
but also raises serum calcium by stimulating intestinal
calcium absorption and bone resorption.18 When used in
conjunction with calcium-based phosphorus binders or
dialysate with high calcium concentrations, calcitriol may
increase the risk for hypercalcemia19 and potentially for
coronary artery calcification.4,20 Two vitamin D2 analogs,
paricalcitol (19-nor-1a,25-dihydroxyvitamin D2; Zemplar,
Abbott Laboratories)21–23 and doxercalciferol (1a-hydroxy-
vitamin D2; Hectorol, Genzyme)24,25 are currently available
for the treatment of secondary hyperparathyroidism.
Although both these analogs have a vitamin D2 side chain,
they differ in their binding kinetics and metabolism. Both
paricalcitol and doxercalciferol resemble calcitriol in their
ability to lower PTH but have more modest effects on serum
calcium and phosphorus concentrations.18,23,25,26
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Differences in clinical outcomes among HD patients
receiving paricalcitol and calcitriol have been described.27–29
In a retrospective analysis of patients on HD at for-profit
facilities, Teng et al.27 reported that mortality was lower
among those treated with paricalcitol compared to calcitriol.
Unfortunately, this report was restricted to patients dialyzed
in facilities operated by a large for-profit provider and did
not include patients who received doxercalciferol.
The present study was conducted to explore the relation-
ship between each vitamin D analog currently available and
mortality among patients starting HD at facilities operated by
Dialysis Clinic Inc. (DCI), a not-for-profit organization.
Mortality was also assessed for patients who did not receive
vitamin D versus those who did.
RESULTS
Of the 14 967 patients who started HD at DCI during the
study period, 8112 received vitamin D and 7731 survived
X30 days after the first vitamin D administration. Twenty-
eight percent of all patients received an initial dose of vitamin
D within 30 days and 47% within 180 days of starting HD.
Patients were censored at death (n¼ 1326), kidney transplant
(n¼ 352), switch to peritoneal dialysis (n¼ 222), prolonged
absence from a DCI clinic (n¼ 967), change in type of
vitamin D (n¼ 2901) or study end (n¼ 1963).
Distributions of age, gender, and cause of ESRD in the
study sample were similar to those of United States Renal
Data Systems (USRDS) 2002 incident cohort1 (data not
shown). Reflecting DCI’s total patient population, African
Americans were over-represented in the study sample (44.5
versus 29.6%). Distributions of demographics and baseline
laboratory values stratified by type of vitamin D are shown
(Table 1). The proportions of female, White and Black
subjects were similar in the three groups. As calcitriol was the
first available vitamin D analog, follow-up time was longer
for patients started on calcitriol versus paricalcitol and
doxercalciferol (Po0.0001). Median time on HD before the
first vitamin D administration was shorter for patients
receiving calcitriol (18 days) compared to paricalcitol or
doxercalciferol (37 days for both) (Po0.0001). The median
number of vitamin D administrations per week was
significantly, but only slightly, greater for calcitriol. Although
the absolute dose of vitamin D (micrograms per week)
differed between the three analogs, the effective dose, using
Table 1 | Study population demographic characteristics and baseline laboratory values by type of vitamin D
Calcitriol (n=3212) Paricalcitol (n=2087) Doxercalciferol (n=2432)
Demographic characteristics
Femalea 48.7 49.0 47.9
Racea
White 49.5 49.6 49.0
Black 44.5 42.8 46.0
Other/unknown 5.9 7.6 6.2
Cause of ESRDa
Diabetes 44.6 45.4 44.4
Hypertension 26.0 25.7 27.1
Glomerulonephritisb 11.6 9.8 9.5
Other/unknown 17.7 19.1 19.0
Age (years)c 62 (32–83) 61 (32–83) 62 (33–83)
Follow-up (weeks)c,d 41 (2–171) 39 (2–153) 32 (2–124)
Time on HD before start of vitamin D (days)c,d 18 (0–328) 37 (0–615) 37 (0–749)
Vitamin D dosee
No. of administrations/weekc,d 2.7 (0.5–3.0) 2.6 (0.5–3.0) 2.6 (0.6–3.0)
Dose/week (mg)c,d 1.6 (0.3–4.7) 7.5 (1.3–18.7) 5.7 (1.1–12.3)
Baseline laboratory valuesc
Calcium (mg/dl)d 8.5 (7.2–9.7) 8.8 (7.6–10.1) 8.8 (7.6–9.9)
Phosphorus (mg/dl)d 5.0 (3.1–7.4) 5.1 (3.4–7.6) 5.1 (3.3–7.5)
PTH (pg/ml)d 289 (52–862) 318 (98–903) 335 (103–881)
Hct (%)d 32.3 (25.6–39.1) 33.9 (27.1–40.0) 34.5 (27.3–40.6)
Kt/Vd 1.3 (0.8–1.9) 1.4 (0.9–1.9) 1.4 (0.9–1.9)
Creatinine (mg/dl)d 6.5 (3.3–12.2) 6.9 (3.7–12.9) 6.9 (3.7–12.7)
Albumin (g/dl)d 3.55 (2.65–4.17) 3.60 (2.75–4.13) 3.60 (2.80–4.17)
ESRD, end-stage renal disease; Hct, hematocrit; HD, hemodialysis; PTH, parathyroid hormone.
aPercent.
bSignificantly different by type of vitamin D, Po0.05 by Pearson w2 test.
cMedian with fifth and 95th percentiles.
dSignificantly different by type of vitamin D, Po0.0001 by Kruskal–Wallis test.
eOver the first 90 days after initiation of vitamin D.
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the dose equivalencies accepted in current clinical practice
(1:4 for paricalcitol to calcitriol; 0.6:1 for doxercalciferol to
paricalcitol),21,31 were similar in the three groups. Reflecting
current clinical practice recommendations, the number of
administrations and vitamin D dose were lower among
patients receiving paricalcitol and doxercalciferol with base-
line PTHo150 pg/ml compared to those with PTHX150 pg/
ml. However, this difference was not observed in calcitriol-
treated patients (data not shown). Baseline serum calcium,
phosphorus, PTH, hematocrit, Kt/V, creatinine, and albumin
were lower among calcitriol- versus paricalcitol- or dox-
ercalciferol-treated patients (Po0.0001). No differences in
baseline laboratory values were observed between the
paricalcitol and doxercalciferol group.
Mortality among patients receiving different vitamin D
analogs
The overall mortality rate (deaths/100 patient-years) in the
study population was lower (17.3. (95% confidence interval:
16.4–18.3)) than that of the 2002 USRDS HD prevalent
cohort (20.9).1 Mortality was significantly higher among
patients receiving calcitriol (19.6 (18.2–21.1)) compared to
those receiving paricalcitol (15.3 (13.6–16.9)) (Po0.0001) or
doxercalciferol (15.4 (13.6–17.1)) (P¼ 0.0003). Similar mor-
tality rates were observed during the 2001–2004 period, when
all three analogs were in use within DCI (overall: 16.3
(15.1–17.5); calcitriol: 19.9 (17.0–22.8); paricalcitol: 15.4
(13.4–17.3); doxercalciferol: 15.4 (13.7–17.2)). Kaplan–Meier
survival curves for patients receiving calcitriol, paricalcitol, or
doxercalciferol are shown (Figure 1). The survival curves for
doxercalciferol- and paricalcitol-treated patients are similar.
Calcitriol-treated patients had worse survival compared to
those receiving either vitamin D2 analog (Po0.0001). In all
models, all-cause mortality was similar among paricalcitol-
versus doxercalciferol-treated patients. The estimates of the
hazard ratios (HRs) for paricalcitol versus doxercalciferol
ranged from 0.99 to 1.06 and were not significantly different
from 1.0 (Table 2). In the unadjusted model, mortality was
lower among patients receiving doxercalciferol (HR¼ 0.80
(0.69–0.91)) and paricalcitol (0.78 (0.69–0.89)) versus
calcitriol (Po0.05). However, when models were adjusted
for laboratory values and clinic standardized mortality
(SMR), the HRs for doxercalciferol and paricalcitol versus
calcitriol both increased and were not statistically significant.
Results of the intent-to-treat analyses also demonstrated
virtually identical mortality among doxercalciferol- and
paricalcitol-treated patients, with HRs ranging from 0.95 to
1.03. HRs tended to be lower among patients treated with
either D2 analog versus calcitriol, but this difference was not
statistically significant in models adjusted for laboratory
values (HRs between 0.96 and 1.00). Similar results were
obtained in analyses restricted to the 2001–2004 period.
ASCVD mortality was similar among doxercalciferol- and
paricalcitol-treated patients and higher among patients
receiving calcitriol in the unadjusted but not in the adjusted
models (data not shown).
Mortality among patients who did not receive vitamin D
therapy
Patients who did not receive vitamin D therapy (n¼ 6855) were
older, more likely to be male subjects and less likely to be Black
subjects. At baseline they had higher serum calcium (8.8
(fifth–95th percentile: 7.5–10.0) versus 8.6 (7.2–9.9) mg/dl),
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Figure 1 | Kaplan–Meier survival curves by type of vitamin D
analog after the first vitamin D administration. *Po0.001 for
patients receiving calcitriol compared to patients on paricalcitol
or doxercalciferol.
Table 2 | Hazard ratios (95% confidence intervals) for all-cause mortality for patients receiving doxercalciferol and paricalcitol
compared to calcitriol-treated patients and for patients receiving paricalcitol versus calcitriol
Model Covariates
Doxercalciferol
vs calcitriol
Paricalcitol vs
calcitriol
Paricalcitol vs
doxercalciferol
1 Unadjusteda 0.80 (0.69, 0.91)b 0.78 (0.69, 0.89)b 0.99 (0.84, 1.15)
2 Age, gender, race, cause of ESRD, year started HD, and time on
HD before first vitamin D administrationa
0.80 (0.66, 0.96)b 0.79 (0.68, 0.92)b 0.99 (0.83, 1.17)
3 Model 2 plus baseline serum calcium, phosphorus, PTH, albumin,
Kt/V, creatinine, and Hct labsc
0.88 (0.71, 1.09) 0.93 (0.78, 1.11) 1.06 (0.88, 1.27)
4 Model 3 plus clinic SMRc 0.93 (0.75, 1.15) 0.94 (0.79, 1.13) 1.02 (0.84, 1.23)
5 Model 4 with time-varying labsc 0.95 (0.77, 1.18) 0.95 (0.79, 1.13) 1.00 (0.82, 1.21)
ESRD, end-stage renal disease; Hct, hematocrit; HD, hemodialysis; PTH, parathyroid hormone; SMR, standardized mortality.
aPatients, n=7731; deaths, n=1326.
bPo0.05.
cPatients, n=6107; deaths, n=1029.
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lower phosphorus (4.5 (2.6–7.4) versus 4.7 (2.8–7.5) mg/dl),
and lower albumin (3.4 (2.5–4.1) versus 3.5 (2.6–4.1) g/dl)
compared to patients who received any vitamin D analog.
Serum calcium concentration did not change over the first 90
days on HD (9.0 mg/dl) Patients who did not receive vitamin
D had a significantly increased mortality risk with a HR of
1.20 after adjustment for patient demographics, baseline
laboratory values, and clinic SMR (Table 3).
Effects of vitamin D analogs on serum calcium, phosphorus,
and PTH
Changes in serum calcium, phosphorus, and PTH concen-
trations over the first 3 months of vitamin D therapy were
assessed in a subcohort of patients who received the same
vitamin D analog and were followed forX90 days (calcitriol:
n¼ 2667; paricalcitol: n¼ 1697; doxercalciferol: n¼ 2010). In
all vitamin D groups, serum calcium, and phosphorus
concentrations increased rapidly over the first month of
vitamin D therapy and slower thereafter (Figure 2). The
mean increment in serum calcium was greater among
calcitriol- (0.7 mg/dl; percent increase¼ 8.2%) compared to
paricalcitol- or doxercalciferol-treated patients (0.5 mg/dl;
5.7% for both) (Po0.0001). However, because of the lower
mean serum calcium concentration at baseline, patients
receiving calcitriol had lower mean serum calcium after 3
months on vitamin D. After 6 months of vitamin D therapy,
serum calcium was similar in the three groups (data not
shown). Serum PTH concentrations decreased similarly in
the three vitamin D groups. However, the mean PTH
concentrations at baseline and after 3 months of therapy
were lower among calcitriol- versus doxercalciferol- and
paricalcitol-treated patients (Figure 2).
Compliance with KDOQI guidelines for bone metabolism and
disease
In an analysis restricted to patients who received a single type
of vitamin D and who had a follow-up time X180 days
(calcitriol: n¼ 1655; paricalcitol: n¼ 1129; doxercalciferol:
n¼ 1354), we assessed achievement of KDOQI guidelines for
calcium, phosphorus, and PTH at baseline and after 6
months on vitamin D (Figure 3).15 Compliance for the entire
study group exceeded those previously reported for the US
cohort in the Dialysis Outcomes and Practice Patterns
Study.32 At baseline, calcitriol-treated patients had worse
compliance for calcium compared to either vitamin D2
analog Po0.001) and better compliance for PTH compared
to doxercalciferol (P¼ 0.0037). After 6 months, compliance
with guidelines for calcium was similar in the three groups
whereas compliance with PTH guidelines was lower among
calcitriol-treated patients (Po0.05).
Table 3 | Hazard ratios (95% confidence intervals) for
all-cause mortality for patients who did not receive any
vitamin D compared to those who received any type of
vitamin D analogue
Model Covariates Hazard ratios (95% CI)
1 Unadjusteda 1.53 (1.43, 1.63)b
2 Age, gender, race, cause of ESRD,
and year started HDa
1.28 (1.20, 1.37)b
3 Model 2 plus baseline calcium,
phosphorus, PTH, albumin, Kt/V,
creatinine, and Hctc,d
1.21 (1.10, 1.33)b
4 Model 3 plus clinic SMRe 1.20 (1.10, 1.32)b
CI, confidence interval; ESRD, end-stage renal disease; Hct, hematocrit; HD, hemo-
dialysis; PTH, parathyroid hormone; SMR, standardized mortality.
aPatients, n=14 967; deaths, n=4238.
bPo0.05.
cPatients, n=9355; deaths, n=2725.
dBaseline laboratory over the first 30 days on HD.
ePatients, n=9351; deaths, n=2723.
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Figure 2 | Mean serum calcium, phosphorus, and PTH concen-
trations over the first 3 months of vitamin D therapy. Restricted
to patients who received the same type of vitamin D and were
followed for X90 days (calcitriol: n¼ 2667; paricalcitol: n¼ 1697;
doxercalciferol: n¼ 2010). Vertical bars indicate the 95% confidence
interval for the mean. Geometric means are shown for PTH. Because
PTH is measured quarterly, means are given only before initiation of
vitamin D (month 0) and after 3 months.
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DISCUSSION
The major new finding of the present study is that
paricalcitol-treated patients do not have a survival advantage
compared to doxercalciferol-treated patients. In fact, the risks
for all-cause and ASCVD mortality were identical in the
paricalcitol and doxercalciferol groups. In all the models
comparing these two vitamins D2 analogs, the estimates for
the HRs were virtually 1.0. Therefore, at least within not-
for-profit facilities, treatment with doxercalciferol compared
to paricalcitol was not associated with increased mortality.
A second important finding of the present study is that the
survival advantage of paricalcitol- versus calcitriol-treated
patients may be significantly smaller than previously
reported.27 Although mortality risk was increased among
patients receiving calcitriol versus paricalcitol and doxer-
calciferol in unadjusted models, these differences diminished
and were not statistically significant in models adjusted for
important covariates. These results suggest that within not-
for-profit facilities, differences in mortality between patients
receiving vitamin D2 versus vitamin D3 analogs may be
smaller than previously reported.27 Several factors, including
differences in practice patterns and in racial composition may
have contributed to the smaller differences observed in the
current study compared to Teng et al.27
Finally, we confirmed the increased risk for mortality
among patients who did not receive vitamin D therapy
compared to those who did. Our results expand previous
reports to patients on HD in a not-for-profit dialysis provider
and receiving a third vitamin D analog.
Although the reasons for the higher mortality observed
among calcitriol-treated patients have not clearly been
identified, several factors related both to the vitamin D
analogs mechanisms of actions and to the study population
should be considered.
Vitamin D receptors are expressed in different tissues
throughout the body, including vascular smooth muscle cells,
lymphocytes, osteoblasts, and cardiac myocytes.33,34 Human
and animal studies have demonstrated that vitamin D affects a
variety of biological processes, including renin expression,35
inflammatory response,36,37 oxidative stress,38 apoptosis,39 and
atherosclerosis.40,41 By activating Vitamin D receptors in different
tissues, vitamin D analogs impact arterial calcification, athero-
sclerosis and inflammatory pathways in a manner independent of
the effects on calcium, phosphorus, and PTH.34 Because of the
differences in structure, binding to Vitamin D receptors and
metabolism18 vitamin D2 and D3 analogs are likely to differ in
the way they impact these processes, therefore contributing to
differences in mortality observed.
Finally, differences in cellular toxicity reported for
calcitriol and paricalcitol in animal studies42,43 may also
contribute to the observed difference in mortality. Compared
to the vitamin D2 analogs, calcitriol may have a greater
tendency to increase serum calcium concentration.19,26 High
serum calcium concentrations per se have been associated
with increased mortality.44 Furthermore, high calcium
concentration contributes to arterial calcifications and
subsequent increase in mortality.34 However, in the present
study although the mean increment in serum calcium was
significantly higher among calcitriol-treated patients, mean
serum calcium concentrations during the first 3 months of
vitamin D therapy were lower in this group compared to
paricalcitol and doxercalciferol. After 6 months of vitamin D
therapy, serum calcium concentrations were similar among
all three groups. Therefore it is unlikely that differences in
serum calcium contributed to the difference in mortality
observed in the three vitamin D groups.
Low serum PTH has also been associated with increased
mortality risk.13 After 3 months of therapy, mean PTH was
below the current KDOQI recommendations15 in all three
vitamin D group. However, most of the follow-up of this
study occurred before publication of the current guidelines
(October 2003). The low PTH concentration observed
among calcitriol-treated patients may have contributed to
their increased mortality risk.
We recognize that selection bias may have contributed to
the specific findings of the current study. The majority of
calcitriol-treated patients began HD before the introduction
of KDOQI guidelines. Although the analyses were adjusted
for the year of initiation of HD, there may have been a
significant residual vintage effect reflecting changing practice
patterns. Patients who had lower serum calcium concentra-
tions at baseline may have preferentially been placed on
calcitriol. Confounding by clinic-level effects may also have
contributed to the observed results. However, across DCI the
choice of one vitamin D analog over the others is often made
at a clinic- rather than a patient-level. Although DCI
corporate guidelines for serum calcium, phosphorus, and
PTH were in place during the study period, treatment of
secondary hyperparathyroidism was not protocol driven.
Because of the large number of clinics and the relatively small
number of patients within most clinics, we did not construct
separate models for each clinic. We did, however, take the
clinic effect into account by creating models that included
clinic SMRs as a covariate, as reported previously by other
authors.27,30 In these models, the estimates of the HRs for
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Figure 3 | Compliance rates with KDOQI guidelines for bone
metabolism and disease at baseline and after 6 months of
vitamin D therapy. Restricted to patients who received a single type
of vitamin D and were followed for X180 days (calcitriol: n¼ 1655;
paricalcitol: n¼ 1129; doxercalciferol: n¼ 1354). Current KDOQI
guidelines: calcium 8.4–9.5 mg/dl; phosphorus 3.5–5.5 mg/dl;
PTH: 150–300 pg/ml. *Po0.05 for calcitriol versus paricalcitol and
doxercalciferol; **Po0.05 for calcitriol versus doxercalciferol.
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doxercalciferol and paricalcitol versus calcitriol were closer to
1.0 than in models not including clinic SMR. These
observations are consistent with the hypothesis that differ-
ences in practice patterns by clinic and possibly by physician
within each clinic may have contributed to the observed
differences in mortality.
In the present study, inclusion of clinically important
covariates in the survival models resulted in HRs for
doxercalciferol and paricalcitol versus calcitriol that were
closer to 1.0. Similar changes in the HRs are also seen in the
models reported by Teng et al. but, in contrast to the present
study, the differences between calcitriol and paricalcitol
remained statistically significant. This likely reflects the larger
sample size and higher mortality rates of Teng’s cohort.
Increased mortality, attributed to difference in clinical
practices, has been reported among patients receiving HD
at for-profit compared to not-for-profit facilities.45 These
authors postulated that differences in staffing and shorter
duration of HD sessions may have contributed to the
increased mortality in for-profit facilities. Although data on
these covariates were not included in the current study,
similar differences in practice patterns may have occurred at
DCI clinics during the study period contributed to the
disparate results between the present study and that reported
by Teng et al.27 Furthermore, the higher proportion of Black
subjects may also have contributed to the improved survival
of the study sample.
Finally, it should be noticed that compliance rates with
KDOQI guidelines for bone metabolism in the current study
exceeded those previously reported for the US cohort in the
Dialysis Outcomes and Practice Patterns Study.32 This may
have contributed to the overall lower mortality rates observed
in the study population.
Overall these observations are consistent with the
hypothesis that there may be confounding by important,
yet unidentified, covariates that contribute to the differences
in survival observed in the three vitamin D groups.
The present study has several limitations characteristic of
most retrospective studies. Comorbidity was not assessed
using a formal instrument, for example, Index of Coexistent
Disease. However, analyses were adjusted for surrogate
markers of comorbidity (age, gender, race, cause of ESRD,
and serum albumin) that took into account the major
comorbid factors among HD patients. Moreover, serum
albumin concentration is an excellent surrogate for formal
comorbidity assessment among ESRD patients. Analysis of
the Choices for Healthy Outcomes in Caring for End-Stage
Renal Disease (CHOICE) Cohort Study demonstrated that
lower serum albumin concentrations were associated with
higher Index of Coexistent Disease severity scores.46 Given
the differences in vintage among patients receiving different
vitamin D analogs, there may have been significant
differences in baseline comorbidity. However, in the USRDS
incident HD population, comorbidity has increased over
time.1 Therefore, as doxercalciferol- and paricalcitol-treated
patients tended to start HD at a later date than calcitriol-
treated patients it is unlikely that they had less baseline
comorbidity. Another major limitation is that owing to lack
of reliable data in the earlier years we were unable to include
important covariates, including oral medications, type of
vascular access, and parathyroidectomies.
Our study also has several unique strengths. The study
sample included only incident patients starting HD at a DCI
facility; therefore, we were able to rule out potential bias and
confounders related to previous medical care that are typical
of prevalent cohorts. All routine laboratory parameters were
analyzed at the same laboratory. Finally, DCI’s proprietary
medical information system (DARWIN) ensured high quality
of the data.
In summary, we demonstrated that doxercalciferol and
paricalcitol are equivalent in their effects on serum calcium,
phosphorus and PTH concentrations and in their relation-
ships with mortality. In addition the differences in mortality
risk between vitamin D2- and D3-treated patients may be
smaller than reported previously. However, given the
inherent limitations of retrospective analyses, a prospective
randomized controlled clinical trial is needed to confirm
these findings.
MATERIALS AND METHODS
Study sample
We studied 14 967 patients agedX20 years who started chronic HD
at a DCI facility during the period of 1 January 1999 to 30
September 2004 and who survived forX30 days. Patients with prior
renal transplant or peritoneal dialysis were excluded. Data were
extracted from DCI’s computerized medical information system
(DARWIN). Dates and causes of death were obtained from the
Centers for Medicare and Medicaid Services (CMS) Death
Notification forms (2746), confirmed by direct contact with each
facility and coded using the International Classification of Disease,
ninth revision (ICD-9).
Laboratory methods
At DCI clinics all laboratory values included in the current study are
measured monthly, except PTH, which is measured quarterly. Blood
samples for routine laboratory determinations were drawn before
initiation of HD and shipped to DCI central laboratory (Nashville,
TN, USA) for analysis. Serum calcium was measured by
Cresolphthalein Complexone (Roche, Nutley, NJ, USA), phosphorus
by Phosphomolybdate-UV (Roche), PTH by N-tact IIPTH SP IRMA
(DiaSorin, Stillwater, MN, USA), blood urea nitrogen by enzymatic
urease (Roche), creatinine by enzymatic creatininase (Roche),
hematocrit by Advia (Bayer, Tarrytown, NY, USA) and serum
albumin by BCG (Roche). Dialysis dose, expressed as spKt/V (Kt/V),
was computed using UREAKINTM. Results of laboratory studies are
electronically imported into DARWIN.
Statistical methods
We compared survival by type of vitamin D among the 7731
patients who ever received vitamin D and who survived for X30
days after the first administration. This 30-day period was chosen
because it allowed time to obtain baseline data and only reduced the
sample size by 381 patients. Follow-up was censored at death, kidney
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transplant, switch to peritoneal dialysis, absence from DCI for X90
days, or study end. Follow-up was also censored if vitamin D type
changed but not if vitamin D was interrupted or discontinued.
Mortality risk was assessed using a series of Cox proportional hazard
models. Model covariates included demographics (age at start of
HD, gender, race, cause of ESRD, year started HD, and time on HD
before first vitamin D administration) and laboratory values (serum
calcium, phosphorus, PTH, albumin, creatinine, hematocrit, and
Kt/V). Baseline values for each laboratory parameter were computed
as the average of measurements taken in the 90-day period before
start of follow-up. Patients with missing baseline measurements
were excluded from adjusted models. Additional models were
constructed in which laboratory values were treated as time-varying
covariates, defined as the average value over the preceding 90 days. If
a given value was missing we substituted the value for the previous
90-day period. To adjust for clinic-level effects models were adjusted
for the SMR of the clinic where HD was initiated.1,27,30 Clinics SMRs
were calculated for the 1998–2003 period and categorized by
quintiles.
Separate sets of models were constructed to conduct intent-to-
treat analyses and for the 2001–2004 study period, when all three
vitamin D analogs were used at DCI clinics.
We also compared mortality between patients who did not
receive vitamin D therapy and those who received any vitamin D
analog. For these analyses follow-up began 30 days after initiation of
HD and patients were classified as not receiving vitamin D up to the
day of first vitamin D administration. Follow-up was censored as
described above. Baseline laboratory values were defined at the
average of all measurements taken in the first 30 days of HD.
Changes in serum calcium, phosphorus, and PTH concentrations
were evaluated among patients who received a single type of vitamin
D therapy and hadX90 days of follow-up. Mean serum calcium and
phosphorus concentrations were computed for the 30 days before
initiation of vitamin D and for 30-day intervals centered at each of the
3 succeeding months. As PTH was measured quarterly, mean values
were computed only at initiation of vitamin D therapy and at 90 days.
Summary data for demographic and laboratory variables are
presented as percents or medians with the fifth and 95th percentiles, as
appropriate. Cox model results are summarized by HR and 95%
confidence intervals. Comparisons between patients receiving different
vitamin D analogs were performed by Pearson w2 and Kruskal–Wallis
tests. Statistical significance was defined as Po0.05. Statistical analyses
were conducted in SAS version 9.1 (Cary, NC, USA)
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